Products >> Molecular Diagnostics >> Reagents & Kits >> Quantitative Molecular Kits for Oncohematology
 .............................................................................................................................................................................................
 

Quantitative Molecular Kits for Oncohematology

Ipsogen has developed a comprehensive range of quantitative assays for AML; ALL and MPD1 including CML allowing a sensitive and quantitative measurement of circulating abnormal genes to monitor the treatment response and disease evolution in leukemia patients. All Ipsogen products are developed and manufactured in regulatory compliant facilities and many are registered as CE marked IVD2. In 2007 Ipsogen is applying for ISO 13485 accreditation. Our products are available today in over 40 countries thanks to a professional manufacturing and marketing organization, and a reliable distribution network. 

Ipsogen R&D efforts are based on internal research and international collaborations. In Europe, Ipsogen is an active player in collaborative networks such as EAC3, ELN4, CONTICANET5 and COBRED6.

FusionQuant® Kits

Unique molecular kits providing standardization and accurate quantification of fusion gene transcripts in leukemia.

Reference Name/Description
FQPP01 AML1ETO FusionQuant® Kit
FQPP02 CBFβMYH11 Type A FusionQuant® Kit
FQPP05CE PMLRARA bcr1 FusionQuant® Kit
FQPP06 PMLRARA bcr2 FusionQuant® Kit
FQPP07 PMLRARA bcr3 FusionQuant® Kit
FQPP09CE BCRABL mbcr FusionQuant® Kit (ABL)
FQPP09GUS BCRABL mbcr FusionQuant® Kit (GUS)
FQPP09BCR BCRABL mbcr FusionQuant® Kit (BCR)
FQPP10CE BCRABL Mbcr FusionQuant® Kit (ABL)
FQPP10GUS BCRABL Mbcr FusionQuant® Kit (GUS)
FQPP10BCR BCRABL Mbcr FusionQuant® Kit (BCR)
FQPP10MCE BCRABL Mbcr FusionQuant® Mega Kit (ABL)
FQPP10DXCE BCRABL Mbcr Dx FusionQuant® Kit
FQPP10DXminCE BCRABL Mbcr Dx FusionQuant® Mini Kit
FQPP10RQCE BCRABL Mbcr RQ FusionQuant® Kit
FQPP11 TEL – AML1 FusionQuant® Kit
RT01CE RTDx Kit

MutaQuantTM Kits

JAK2 V617F mutation assays allow qualitative and quantitative detection of the JAK2 V617F mutation from genomic DNA isolated from peripheral blood.
These tests improve the classification of Philadelphia Negative (Ph-) myeloproliferative neoplasms.
 

Reference Name/Description
MQPP01 JAK2 MutaQuant™ Kit (Quantitative)
MQPP02 JAK2 MutaQuant™ Kit (Quantitative)
MQPP03 JAK2 MutaQuant™ Mini Kit
MQPP04 NPM1 mut A MutaQuant™ Kit
MQPP05 NPM1 mut B & D MutaQuant™ Kit

MutaScreenTM Kits

Reference Name/Description
MSPP01CE JAK2 MutaScreen™ Kit
MSPP01EZCE JAK2 MutaScreen™ EZ Kit
MSPP02CE JAK2 MutaScreen™ Mini Kit
MSPP03CE JAK2 MutaScreen™ Kit & Ref. Scale
MSPP10 MPL W515L/K MutaScreen™ Kit

MutaSearchTM Kits

Reference Name/Description
MSPP05 JAK2 MutaSearch™ Kit

MutaQuant™ Standards

MutaQuant™ Standards are available for specific detection of polymorphisms from both RNA and genomic DNA samples.

Reference Name/Description
MQRS01 NPM1 mut A cDNA MutaQuant™ Standard
MQRS01G NPM1 mut A gDNA MutaQuant™ Standard
MQRS02 NPM1 mut B et D cDNA MutaQuant™ Standard
MQRS02G NPM1 mut B et D gDNA MutaQuant™ Standard
CGRS01 ABL FusionQuant® Control Gene Standards
CGRS02 B2M FusionQuant® Control Gene Standards
CGRS03 GUS FusionQuant® Control Gene Standards
CGRS04 TBP FusionQuant® Control Gene Standards
CGRS05 BCR FusionQuant® Control Gene Standards
CFGR29 SRY3 FusionQuant® Control Gene Standards
CFGR30 βGlobine FusionQuant® Control Gene Standards
FGRS01 AML1–ETO FusionQuant® Fusion Gene Standards
FGRS02 CBFβMYH11 A FusionQuant® Fusion Gene Standards
FGRS03 CBFβMYH11 D FusionQuant® Fusion Gene Standards
FGRS04 CBFβMYH11 E FusionQuant® Fusion Gene Standards
FGRS05 PMLRARA bcr1 FusionQuant® Fusion Gene Standards
FGRS06 PMLRARA bcr2 FusionQuant® Fusion Gene Standards
FGRS07 PMLRARA bcr3 FusionQuant® Fusion Gene Standards
FGRS08 E2APBX1 FusionQuant® Fusion Gene Standards
FGRS09 BCRABL mbcr FusionQuant® Fusion Gene Standards
FGRS10 BCRABL Mbcr FusionQuant® Fusion Gene Standards
FGRS11 TEL – AML1 e4e11 FusionQuant® Fusion Gene Standards
FGRS12 SILTAL FusionQuant® Fusion Gene Standards
FGRS13 MLLAF4 e10e4 = RS411 type FusionQuant® Fusion Gene Standards
FGRS14 MLLAF4 e9e5 = MV411 type FusionQuant® Fusion Gene Standards
FGRS15 MLLAF4 e11e5 = ALLPO type FusionQuant® Fusion Gene Standards
FGRS16 MLLAF9 type A e10e6 FusionQuant® Fusion Gene Standards
FGRS17 MLLAF9 type B e8e9 FusionQuant® Fusion Gene Standards
FGRS18 MLLAF6 e8e2 FusionQuant® Fusion Gene Standards
FGRS19 MLLDUP e2e8 FusionQuant® Fusion Gene Standards
FGRS20 MLLENL e9e2 FusionQuant® Fusion Gene Standards
FGRS21 MLLENL e10e2 FusionQuant® Fusion Gene Standards
FGRS23 MLLAF9 e8e10 FusionQuant® Fusion Gene Standards
FGRS24 MLLELL e9e2 FusionQuant® Fusion Gene Standards
FGRS25 MLLELL e8e2 FusionQuant® Fusion Gene Standards
FGRS26 MLLAF1p e10e2 FusionQuant® Fusion Gene Standards
CFGR27 RARAPML bcr12 FusionQuant® Fusion Gene Standards
CFGR28 RARAPML bcr3 FusionQuant® Fusion Gene Standards

Control cell lines

Control cell lines are ideal tools for the control of total RNA extraction and transcription steps in the context of specific rearrangement detection by quantitative PCR.
One vial of control cell line should be processed in parallel with one batch of samples using the same reagents and protocols.

Reference Name/Description
PCCL01 High BCRABL Mbcr Control Cell Line
PCCL02 High BCRABL mbcr Control Cell Line
PCCL03 Low BCRABL Mbcr Control Cell Line
PCCL04 Low BCRABL mbcr Control Cell Line
PCCL05 Negative BCRABL Mbcr & mbcr Control Cell Line
PCCL06 High PMLRARa bcr1 Control Cell Line
PCCL07 Low PMLRARa bcr1 Control Cell Line
PCCL08 Negative PMLRARa Control Cell Line
CLCK01 High, Low and Negative BCRABL Mbcr Control Cell Line Kit
CLCK02 High, Low and Negative BCRABL mbcr Control Cell Line Kit
CLCK03 High, Low and Negative PMLRARa bcr1 Control Cell Line Kit

ProfileQuant® Kits

Unique quantitative molecular kits aimed at standardizing, detecting and quantifying profile gene transcripts in human cells.

Reference Name/Description
PQPP02CE WT1 ProfileQuant® Kit
PQPP03 BAALC ProfileQuant® Kit
PQPP04 CLLU1 ProfileQuant® Kit

.............................................................................................................................................................................................